Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting

By Jérémie Calais, MD, PhD - Last Updated: June 20, 2024

Jérémie Calais, MD, PhD, of University of California, Los Angeles, shares his thoughts on the SNMMI 2024 Annual Meeting and the sessions or abstracts that are of the most importance for practicing genitourinary oncologists.

View his continued comments on Dosimetry of ¹⁷⁷Lu-PSMA RLTs, FLEX-MRT, and More.

ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC

Emily MenendezRLT | March 7, 2025

Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.

Comparing OS and PFS Rates of Patients With mCRPC and BRCA, PTEN/TP53/RB1 Mutations

Emily MenendezRLT | January 7, 2025

Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.

PSMAfore: Radioligand Therapy in the Future of Prostate Cancer Treatment

Oliver Sartor, MDRLT | November 21, 2024

Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.

The Landscape of Radiopharmaceuticals and PARP Inhibitors in CRPC

Irbaz B. Riaz, MBBS, PhDCRPC | November 5, 2024

In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.

Uromigos Live 2024 Radioligands Part 5: Novel Radioligands in CRPC

Brian Rini, MD, FASCORLT | October 29, 2024

The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.

Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting

Related Posts